Molecular Biologist Job Description

A Molecular Biologist works on the chemistry of heredity and its products: how DNA is copied and repaired, how genes switch on and off, how RNA is processed, and how proteins fold and pass signals inside a cell. O*NET's profile for Molecular and Cellular Biologists sums up the job as research on cellular molecules and organelles to understand cell function and organization, and it lists "molecular biologist" among the titles workers report.

The bench is where the job lives. A week might include designing guide RNAs for a CRISPR knockout, cloning a construct with Gibson Assembly, transfecting HEK293 cells, running RT-qPCR on the harvest, and checking protein levels with a Western blot. Between those runs sit the less glamorous tasks that decide whether a result holds up: validating antibodies, sequencing plasmids before use, logging lot numbers, and writing everything into an electronic lab notebook so a colleague could repeat it a year later.

Bulk and single-cell RNA-seq, ChIP-seq and ATAC-seq runs produce files that someone has to align, normalize and interpret, and in a small lab that someone may be the molecular biologist who designed the experiment. Protein structure is part of the planning too. The National Science Foundation, congratulating the 2024 chemistry laureates, credited AlphaFold with enabling the determination of a protein's structure from its amino acid sequence alone. A molecular biologist planning a point mutant or a truncated construct can check a predicted structure before ordering a single oligo, then test the hypothesis at the bench.

The setting shapes the goal. In a university lab the output is a paper and the next grant; the Molecular Biologist may also train graduate students and, per O*NET, supervise technical personnel and postdoctoral research fellows. At a biotech or pharmaceutical company the same techniques serve a program: confirming that a target gene drives disease, building the cell lines and reporter assays that screen compounds, or characterizing the vector for a gene therapy. In a clinical or reference laboratory the work turns toward assay development and validation for nucleic acid tests, under quality systems that leave less room for improvisation.

Gene editing offers a concrete case of bench methods reaching a patient. In May 2025 the National Center for Advancing Translational Sciences reported that an NIH-supported team at Children's Hospital of Philadelphia and the University of Pennsylvania had delivered a personalized gene editing therapy to an infant with carbamoyl phosphate synthetase 1 (CPS1) deficiency, and that the process from diagnosis to treatment took six months. Every step of a project like that, from designing the editor to measuring on-target and off-target edits, is molecular biology done to clinical standards.

The job is also a writing job. Grant aims, methods sections, internal study reports and slide decks for program reviews all come from the person who ran the experiments, and the ability to explain a negative result clearly is part of the craft.

Entry into molecular biology runs through a life science degree: molecular biology, biochemistry, genetics, cell biology or a closely related major with real lab coursework. A bachelor's degree can open research assistant and associate scientist roles, where the work is executing protocols other people design. A master's degree adds independent technique development and can serve as a bridge into industry scientist titles. Leading a research program, in a university or a company, generally takes a PhD, and in academia a postdoctoral appointment after that.

O*NET places Molecular and Cellular Biologists in Job Zone Five, its category for occupations that need extensive preparation, and its education survey shows how split the field is: 35% of respondents said a new hire needs a bachelor's degree, 35% said post-doctoral training, and 23% said a doctoral degree. As a rough guide, an industry Scientist title tends to follow a PhD or a master's plus 3 to 5 years at the bench.

Postdoctoral pay is public for anyone funded through NIH training mechanisms. NIH notice NOT-OD-26-044 set the fiscal year 2026 Kirschstein-NRSA stipend at $63,480 for a postdoc with zero years of experience and $29,364 for predoctoral trainees, for awards made on or after October 1, 2025. Knowing that table helps when reading a postdoc offer from any institution.

Core bench skills a hiring manager will probe:

• Nucleic acid work: extraction, PCR and RT-qPCR with sound primer design and controls, gel electrophoresis, Sanger sequencing reads
• Cloning: restriction and ligation, Gibson Assembly, Golden Gate, site-directed mutagenesis
• Genome editing: guide design, delivery by lipofection, electroporation or lentivirus, clone screening and off-target checks
• Protein methods: Western blotting, immunoprecipitation, expression and purification in E. coli or mammalian cells
• Cell culture: aseptic technique, line authentication, mycoplasma testing, cryopreservation
• Sequencing: library preparation for RNA-seq or ATAC-seq and enough command-line comfort to run an alignment and read the QC report

Lab citizenship matters as much as technique. Biosafety training for BSL-2 work, chemical hygiene, institutional biosafety committee approvals for recombinant DNA, and clean notebook practice are all expected before anyone hands over a project. In a regulated company or a clinical lab, add standard operating procedures, deviation reports and audit trails.

Credentials are optional for research jobs. Molecular biologists who move into clinical diagnostics can pursue the Technologist in Molecular Biology, MB(ASCP), awarded by the American Society for Clinical Pathology Board of Certification, whose exam covers molecular science and techniques such as nucleic acid isolation, separation and detection, and amplification.

The strongest applications show a project carried from question to answer: a figure, a dataset, or a validated assay that the candidate can defend line by line in an interview.

BLS counts molecular biologists inside Biological Scientists, All Other, an occupation that also holds other life science specialties, so the national figures describe the group rather than this title alone. The May 2025 OEWS survey counted 55,850 jobs in that occupation. O*NET's projection for 2025 to 2035 rates growth as faster than average, at 5% to 6%, with about 4,300 openings a year on average, and it flags the occupation as Bright Outlook.

Where the job sits changes the paycheck. BLS May 2025 industry data for the occupation put the median annual wage at $107,540 in scientific research and development services, which employed 15,870 of them, $106,880 in pharmaceutical and medicine manufacturing, $97,280 in medical and diagnostic laboratories, and $77,450 at colleges, universities and professional schools. Those industry rows cover the whole occupation, since BLS does not report molecular biologists separately.

For university labs that run on NIH grants, fiscal 2026 brought a small increase rather than a cut. The Congressional Research Service reported in May 2026 that the enacted FY2026 appropriations gave NIH a total program level of $47.493 billion, $458 million or 1.0% above the FY2025 final level. The 15% cap on indirect costs that NIH announced in February 2025 had not taken effect as of that report: CRS noted that a Massachusetts federal court permanently enjoined it in April 2025 and the First Circuit Court of Appeals upheld that ruling on January 5, 2026. Indirect costs pay for facilities and administration, the buildings, core equipment and grant offices a lab relies on, so the ruling matters to anyone weighing a faculty or staff scientist offer.

Diagnostics hiring sits under its own rulebook. FDA's May 2024 final rule had amended its device regulations to add the words "including when the manufacturer of these products is a laboratory," which would have brought laboratory developed tests under device oversight. A federal district court vacated that rule on March 31, 2025, and on September 19, 2025 FDA issued a final rule reverting to the text of the regulation as it existed before. For molecular biologists who build in-house PCR and sequencing assays, that leaves the pre-2024 regulatory text in place.

Industry roles follow pipelines, and gene editing, RNA medicines and cell therapy all depend on molecular biologists to design constructs, build assays and characterize products. That work is tied to specific programs and their milestones. A candidate who can show both wet-lab results and the analysis behind them can apply across research, process development, assay development, and translational science groups that sit between discovery and the clinic.

For anyone planning a long career, the practical advice is to keep one foot in each world. Publish or present work that proves scientific judgment, learn the quality vocabulary that regulated labs use, and keep data skills current enough to own an analysis without waiting in a queue for a bioinformatician.

Dear Dr. Okafor,

I am writing to apply for the Molecular Biologist opening on your target validation team. I finished my PhD in cell and molecular biology at a state university this summer, where my dissertation examined how a family of RNA-binding proteins changes splicing in stressed liver cells.

Most of my thesis was built with CRISPR. I designed and screened knockout and knock-in lines in HepG2 and primary-derived hepatocytes, confirmed edits by amplicon sequencing, and wrote a short script in R to flag off-target sites before we froze any clone. To show that the splicing changes mattered, I paired RNA-seq with minigene reporters and rescue constructs I cloned by Gibson Assembly. That combination of editing, sequencing and functional follow-up is the part of my training I am most eager to bring to your group.

I also learned to work in a shared lab without drama. I ran our tissue culture room for two years, kept the mycoplasma testing schedule, and trained six rotation students on qPCR and Western blotting. When one of my central experiments failed to replicate, I traced the problem to a mislabeled antibody lot, documented it, and rebuilt the figure with a validated reagent before submission.

Your team's focus on metabolic liver disease lines up closely with my thesis system. I would value the chance to apply that experience to programs where a validated target leads to a real decision, not only a paper.

Thank you for your time and consideration. I would be glad to walk through any of my raw data, notebooks or code in an interview.

Sincerely, Maya Lindqvist